Literature DB >> 17997492

Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.

Li-Jun Chi1, Hua-Bing Wang, Ying Zhang, Wei-Zhi Wang.   

Abstract

CD4(+)CD25(+) T regulatory cells (Tregs), a subset of CD4(+) T cells expressing high levels of CD25 and the transcription factor Foxp3, are critical in maintaining immunologic homeostasis and preventing autoimmunity by suppressing self-reactive T cells. Guillain-Barré syndrome (GBS) is thought to be a self-limiting, autoimmune disease of the peripheral nervous system. We hypothesized that altered frequency and/or function of Tregs play a role in the breakdown of immunologic self-tolerance in GBS patients. To characterize Tregs in GBS patients, we used flow cytometry to evaluate peripheral numbers of Tregs, real-time polymerase chain reaction to assay mRNA expression of FOXP3, and coculture to analyze functional suppressive properties of Tregs. The results showed that acute-stage patients with AMAN and AIDP exhibited significantly reduced numbers of peripheral Tregs as compared with healthy donors, but marked improvement was observed in stable-stage patients with GBS after treatment with intravenous immunoglobulin (IVIG), concomitantly with improvement of neuropathic symptoms. On the other hand, GBS-derived Tregs and Tregs from healthy individuals exhibited equal FOXP3-expression of mRNA and their ability of suppressing the proliferation and cytokine secretion of CD4 (+) effector T cells was unimpaired in GBS patients. These results suggest that short-term reduced circulating Tregs may be associated with the pathogenesis of two subtypes of GBS. Reversible number and intact function of Tregs presumably contribute to monophasic self-limiting course in GBS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997492     DOI: 10.1016/j.jneuroim.2007.09.034

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  32 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Immunomodulation by intravenous immunoglobulin: role of regulatory T cells.

Authors:  Mohan S Maddur; Shivashankar Othy; Pushpa Hegde; Janakiraman Vani; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

3.  Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.

Authors:  S Quan; J R Sheng; P M Abraham; B Soliven
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

Review 4.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 5.  Guillain-barré syndrome: modern theories of etiology.

Authors:  Todd A Hardy; Stefan Blum; Pamela A McCombe; Stephen W Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 6.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 7.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

8.  Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.

Authors:  M C González-Oria; M Márquez-Coello; J A Girón-Ortega; J Argente; M Moya; José-Antonio Girón-González
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-16       Impact factor: 4.147

9.  Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.

Authors:  Rong Kun Han; Yue Feng Cheng; Shan Shan Zhou; Hong Guo; Rui Dong He; Li Jun Chi; Li Ming Zhang
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

10.  Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells.

Authors:  A S W Tjon; T Tha-In; H J Metselaar; R van Gent; L J W van der Laan; Z M A Groothuismink; P A W te Boekhorst; P M van Hagen; J Kwekkeboom
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.